EB-NK-301

EB-NK-301 is a CAR-NK cell therapy developed by Beijing Biotech. Its target is TROP2. ClinicalTrials.gov describes the intervention as: Investigational allogeneic CAR-NK cell product targeting TROP2, administered by intravenous infusion. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT07589530, plans to enrol 60 participants with primary completion expected 2027-02-14. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.